Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Hyaluronic Acid,Dermatan Sulfate,Collagen
Therapeutic Area : Dermatology
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
New Study Reveals Bioiberica's Dermial® Delivers Superior Benefits for Skin Health
Details : New pre-clinical study showed that Dermial® hyaluronic acid matrix ingredient increased type I collagen production by almost half – an observation not seen with standard hyaluronic acid from fermentation or extraction origin.
Brand Name : Dermial
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 25, 2022
Lead Product(s) : Hyaluronic Acid,Dermatan Sulfate,Collagen
Therapeutic Area : Dermatology
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Undenatured Type II Collagen
Therapeutic Area : Musculoskeletal
Study Phase : Approved
Sponsor : ByHealth
Deal Size : Undisclosed
Deal Type : Partnership
New Partnership With ByHealth in China
Details : By partnering with Bioiberica, ByHealth aims to capitalise on the untapped potential of new product development with native type II collagen and respond to the growing number of consumers looking to support their mobility with effective, convenient produ...
Brand Name : Collavant n2
Molecule Type : Large molecule
Upfront Cash : Undisclosed
March 11, 2022
Lead Product(s) : Undenatured Type II Collagen
Therapeutic Area : Musculoskeletal
Highest Development Status : Approved
Sponsor : ByHealth
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Chondroitin Sulfate Sodium
Therapeutic Area : Musculoskeletal
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Bioiberica Rebrands Its Range of Nutraceutical Ingredients for Healthcare
Details : Bioiberica’s native (undenatured) type II collagen, Collavant® n2 (previously b2-Cool®) and the addition of Tendaxion® - a new brand for its tendon health ingredient.
Brand Name : CSbioactive
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 05, 2021
Lead Product(s) : Chondroitin Sulfate Sodium
Therapeutic Area : Musculoskeletal
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Hyaluronic Acid,Type II Collagen
Therapeutic Area : Musculoskeletal
Study Phase : Approved
Sponsor : Apsen
Deal Size : Undisclosed
Deal Type : Partnership
Bioiberica and Apsen Reinforce Partnership with New Holistic Mobility Product–Motilex HA
Details : Apsen’s Motilex HA combines two leading ingredients, b-2Cool native type II collagen and Mobilee, patented ingredient that synergistically combines a high concentration of hyaluronic acid with polysaccharides and collagen, to effectively maintain joint...
Brand Name : Motilex HA
Molecule Type : Small molecule
Upfront Cash : Undisclosed
April 26, 2021
Lead Product(s) : Hyaluronic Acid,Type II Collagen
Therapeutic Area : Musculoskeletal
Highest Development Status : Approved
Sponsor : Apsen
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Undenatured Type II Collagen,Chondroitin Sulfate Sodium,Hyaluronic Acid
Therapeutic Area : Musculoskeletal
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The study, conducted in a rabbit model of osteoarthritis, set out to evaluate the effects of b-2Cool native type II collagen in combination with CS b-Bioactive chondroitin sulphate, glucosamine hydrochloride and Mobilee® which is a rooster comb extract ...
Brand Name : Mobilee
Molecule Type : Large molecule
Upfront Cash : Not Applicable
September 07, 2020
Lead Product(s) : Undenatured Type II Collagen,Chondroitin Sulfate Sodium,Hyaluronic Acid
Therapeutic Area : Musculoskeletal
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Undenatured Type II Collagen,Harpagophytum Procumbens Extract,Hyaluronic Acid
Therapeutic Area : Musculoskeletal
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : B-2Cool (Bioiberica’s native type II collagen) is an innovative ingredient, has been shown in four scientific studies to help maintain good joint health at a very low daily dose.
Brand Name : Colnatur Forte
Molecule Type : Large molecule
Upfront Cash : Not Applicable
July 15, 2020
Lead Product(s) : Undenatured Type II Collagen,Harpagophytum Procumbens Extract,Hyaluronic Acid
Therapeutic Area : Musculoskeletal
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Hyaluronic Acid,Type II Collagen,Polysaccharide
Therapeutic Area : Musculoskeletal
Study Phase : Undisclosed
Recipient : Nestle Health Sciences SA
Deal Size : Undisclosed
Deal Type : Partnership
Details : Nestlé Health Science is incorporating Bioiberica’s patented ingredient, Mobilee®, into its MERITENE® Mobilis® joint-health drink mix.
Brand Name : Meritene Mobilis
Molecule Type : Small molecule
Upfront Cash : Undisclosed
June 16, 2020
Lead Product(s) : Hyaluronic Acid,Type II Collagen,Polysaccharide
Therapeutic Area : Musculoskeletal
Highest Development Status : Undisclosed
Recipient : Nestle Health Sciences SA
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Chondroitin Sulfate Sodium,Glucosamine,Hyaluronic Acid
Therapeutic Area : Musculoskeletal
Study Phase : Approved
Recipient : Bayer AG
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under the terms of the agreement, Bayer Animal Health will distribute and market selected products from Bioiberica´s Companion Animal Health portfolio in eight countries.
Brand Name : Condrovet
Molecule Type : Small molecule
Upfront Cash : Undisclosed
June 09, 2020
Lead Product(s) : Chondroitin Sulfate Sodium,Glucosamine,Hyaluronic Acid
Therapeutic Area : Musculoskeletal
Highest Development Status : Approved
Recipient : Bayer AG
Deal Size : Undisclosed
Deal Type : Agreement